Bioventus Inc. BVS
At closeNov 4, 2026, 4:26 PM EST
After hours · Nov 4, 4:26 PM ET
- YTD
- +53.49%
- 1 year
- +51.26%
- Market cap
- 781.98M
- Revenue (ttm)
- 581.85M
- Profit margin
- 9.36%
- EPS (ttm)
- 0.65
- Shares out
- 68.31M
- P/E ratio
- 17.57
- Forward P/E
- 16.16
- YTD return
- +53.49%
- 1-year return
- +51.26%
- Volume
- 1.26M
- Avg volume
- 578.79K
- Open
- 11.24
- Previous close
- 10.95
- Day's range
- 11.17 – 11.93
- 52-week range
- 6.47 – 15.89
- Beta
- 0.64
- Analysts
- Strong Buy
- Price target
- 17.60 (+54.1%)
- Earnings date
- Nov 2, 2026
2Y -0.05 (-0.44%)
Key statistics
- Enterprise value
- 1.28B
- PEG ratio
- 1.53
- Price / sales
- 1.75
- Price / book
- 4.44
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 3.80%
- Free cash flow
- 67.76M
- Total cash
- 30.39M
- Total debt
- 263.75M
- Return on equity
- 25.68%
- Short % of float
- 6.78%
- 50-day average
- 13.72
- 200-day average
- 10.84
Analyst view
Consensus: strong buy
- Target (low)
- 15.00
- Target (mean)
- 17.60
- Target (high)
- 19.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.16.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 27, 2026 | 0.1496 | — | — | — |
| Aug 5, 2026 | Jun 27, 2026 | 0.2163 | 0.22 | 0.00 | +1.71% |
| May 6, 2026 | Mar 28, 2026 | 0.09 | 0.15 | +0.06 | +66.67% |
| Mar 5, 2026 | Dec 31, 2025 | 0.22 | 0.24 | +0.02 | +9.09% |
| Nov 4, 2025 | Sep 27, 2025 | 0.215 | 0.15 | -0.06 | -30.23% |
| Aug 6, 2025 | Jun 28, 2025 | 0.22 | 0.21 | -0.01 | -4.55% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 17, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Jun 30, 2026 | Barrington Research | main | Outperform | Outperform |
| Jun 16, 2026 | Canaccord Genuity | main | Buy | Buy |
| May 22, 2026 | Barrington Research | main | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | main | Outperform | Outperform |
About Bioventus Inc.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bioventus.com
News
Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings 
Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18 
Adeia Posts Downbeat Q3 Earnings, Joins Bioventus, Apple And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Why Aehr Test Systems Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket 
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript 
Bioventus (BVS) Matches Q3 Earnings Estimates 
Bioventus Q3 Earnings Call Highlights 
Bioventus Q3 2026 Earnings Call Transcript 
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est
Your note
Sign in to keep a note on BVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTHOLDSON JOHN A | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 1, 2026 | 7,051,260 |
| CLAYPOOLE ROBERT E. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 12, 2026 | 135,944 |
| D'ADAMIO ANTHONY | General Counsel | Conversion of Exercise of derivative security | Apr 9, 2026 | 153,655 |
| HAWKINS WILLIAM A III | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 297,640 |
| LADONE MARY KAY | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 111,263 |
| NEELS GUIDO J | Director | Conversion of Exercise of derivative security | Jun 1, 2026 | 117,523 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Management Inc. | 19.06% | 13,021,324 | 193.63M | Jun 29, 2026 |
| Juniper Investment Company, LLC | 10.16% | 6,939,357 | 103.19M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 8.78% | 6,000,279 | 89.22M | Jun 29, 2026 |
| Blackrock Inc. | 5.03% | 3,435,914 | 51.09M | Jun 29, 2026 |
| Royce & Associates LP | 2.68% | 1,833,212 | 27.26M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 2.56% | 1,751,678 | 26.05M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.58% | 1,760,427 | 26.18M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.83% | 1,248,896 | 18.57M | Sep 29, 2026 |
| Brown Advisory Funds-Brown Advisory Small-Cap Fundamental Value Fund | 1.81% | 1,239,520 | 18.43M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.70% | 1,163,677 | 17.30M | Jun 29, 2026 |
| ROYCE FUND-Royce Small-Cap Opportunity Fund | 1.26% | 858,738 | 12.77M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.00% | 684,514 | 10.18M | Jun 29, 2026 |